Beam Therapeutics BEAM has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives ...

Given BEAM-302's clean safety profile so far, "we believe it is prudent the company evaluate an additional dose level to see if higher levels of AAT correction and lower mutant AAT levels can be ...